Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help
Search by PDB author
5OPY
DownloadVisualize
BU of 5opy by Molmil
Crystal structure of anti-alphaVbeta3 integrin Fab LM609
Descriptor: Heavy chain of LM609 Fab (antigen-binding fragment), Light chain of LM609 Fab (antigen-binding fragment)
Authors:Backovic, M, Veesler, D, Borst, A.J, James, Z.M, Zagotta, W, Ginsberg, M, Rey, F.A, DiMaio, F.
Deposit date:2017-08-10
Release date:2017-10-25
Last modified:2024-01-17
Method:X-RAY DIFFRACTION (2.26 Å)
Cite:The Therapeutic Antibody LM609 Selectively Inhibits Ligand Binding to Human alpha V beta 3 Integrin via Steric Hindrance.
Structure, 25, 2017
6AVU
DownloadVisualize
BU of 6avu by Molmil
Human alpha-V beta-3 Integrin (open conformation) in complex with the therapeutic antibody LM609
Descriptor: Fab LM609 heavy chain, Fab LM609 light chain, Integrin alpha-V, ...
Authors:Borst, A.J, James, Z.N, Zagotta, W.N, Ginsberg, M, Rey, F.A, DiMaio, F, Backovic, M, Veesler, D.
Deposit date:2017-09-04
Release date:2017-11-01
Last modified:2024-03-13
Method:ELECTRON MICROSCOPY (35 Å)
Cite:The Therapeutic Antibody LM609 Selectively Inhibits Ligand Binding to Human alpha V beta 3 Integrin via Steric Hindrance.
Structure, 25, 2017
6AVQ
DownloadVisualize
BU of 6avq by Molmil
The Therapeutic Antibody LM609 Selectively Inhibits Ligand Binding to Human alpha-V beta-3 Integrin via Steric Hindrance
Descriptor: Integrin alpha-V, Integrin beta-3, LM609 Fab heavy chain, ...
Authors:Borst, A.J, James, Z.N, Zagotta, W.N, Ginsberg, M, Rey, F.A, DiMaio, F, Backovic, M, Veesler, D.
Deposit date:2017-09-04
Release date:2017-11-01
Last modified:2024-03-13
Method:ELECTRON MICROSCOPY (35 Å)
Cite:The Therapeutic Antibody LM609 Selectively Inhibits Ligand Binding to Human alpha V beta 3 Integrin via Steric Hindrance.
Structure, 25, 2017
6AVR
DownloadVisualize
BU of 6avr by Molmil
Human alpha-V beta-3 Integrin (intermediate conformation) in complex with the therapeutic antibody LM609
Descriptor: Fab LM609 heavy chain, Fab LM609 light chain, Integrin alpha-V, ...
Authors:Borst, A.J, James, Z.N, Zagotta, W.N, Ginsberg, M, Rey, F.A, DiMaio, F, Backovic, M, Veesler, D.
Deposit date:2017-09-04
Release date:2017-11-01
Last modified:2024-03-13
Method:ELECTRON MICROSCOPY (35 Å)
Cite:The Therapeutic Antibody LM609 Selectively Inhibits Ligand Binding to Human alpha V beta 3 Integrin via Steric Hindrance.
Structure, 25, 2017
8SU8
DownloadVisualize
BU of 8su8 by Molmil
Co-crystal structure of KRIT1 with a 1-hydroxy 2-naphthaldehyde derivative (6-(furan-2-yl)-2-hydroxy-1-naphthaldehyde).
Descriptor: (6P)-6-(furan-2-yl)-2-hydroxynaphthalene-1-carbaldehyde, Krev interaction trapped protein 1, MAGNESIUM ION, ...
Authors:Bruystens, J.G.H.
Deposit date:2023-05-11
Release date:2023-12-06
Last modified:2024-10-23
Method:X-RAY DIFFRACTION (2.01 Å)
Cite:Targeted Reversible Covalent Modification of a Noncatalytic Lysine of the Krev Interaction Trapped 1 Protein Enables Site-Directed Screening for Protein-Protein Interaction Inhibitors.
Acs Pharmacol Transl Sci, 6, 2023
8T7V
DownloadVisualize
BU of 8t7v by Molmil
Co-crystal structure of KRIT1 with a 1-hydroxy 2-naphthaldehyde derivative (6-(furan-2-yl)-2-hydroxy-1-naphthaldehyde)
Descriptor: (7M)-7-(furan-2-yl)-2-hydroxynaphthalene-1-carbaldehyde, Krev interaction trapped protein 1, MAGNESIUM ION, ...
Authors:Bruystens, J.G.H.
Deposit date:2023-06-21
Release date:2023-12-06
Method:X-RAY DIFFRACTION (2.25 Å)
Cite:Targeted Reversible Covalent Modification of a Noncatalytic Lysine of the Krev Interaction Trapped 1 Protein Enables Site-Directed Screening for Protein-Protein Interaction Inhibitors.
Acs Pharmacol Transl Sci, 6, 2023
8T09
DownloadVisualize
BU of 8t09 by Molmil
Co-crystal structure of KRIT1 with a 1-hydroxy 2-naphthaldehyde derivative (6-ethynyl-2-hydroxy-1-naphthaldehyde)
Descriptor: 6-ethynyl-2-hydroxynaphthalene-1-carbaldehyde, Krev interaction trapped protein 1, MAGNESIUM ION, ...
Authors:Bruystens, J.G.H.
Deposit date:2023-05-31
Release date:2023-12-13
Last modified:2024-10-23
Method:X-RAY DIFFRACTION (2.15 Å)
Cite:Targeted Reversible Covalent Modification of a Noncatalytic Lysine of the Krev Interaction Trapped 1 Protein Enables Site-Directed Screening for Protein-Protein Interaction Inhibitors.
Acs Pharmacol Transl Sci, 6, 2023

226707

PDB entries from 2024-10-30

PDB statisticsPDBj update infoContact PDBjnumon